1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Alpa Laboratories Limited

Alpa Laboratories Limited

51.46
INR
+0.24
(+0.47%)
2.07EPS
32.67P/E
1.42BMarket Cap
Alpa Laboratories Limited
NSE:ALPA
(National Stock Exchange of India)

Recent

price

51.46

P/E

ratio

32.67

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
39.38
26.2
26.72
26.95
27.1
25.44
29.72
29.42
36.32
40.34
45.82
52.52
43.92
51.29
53.06
49.9
52.25
Revenue per Share
0.43
0.25
-2.08
-2.45
-0.66
3.25
1.2
1.33
0.48
0.88
3.44
6.7
5.98
7.97
9.27
7.13
2.07
Basic EPS, GAAP
1.92
-0.75
-0.63
2.79
-1.42
-15.41
7.4
-7.94
-0.88
7.24
-2.34
3.68
3.7
1.73
3.3
2.87
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
46.24
46.5
44.42
41.97
41.14
43.82
45.02
46.36
46.81
47.7
51.16
57.86
63.96
72.2
81.48
88.53
- -
Book Value per Share
46.24
46.5
44.42
41.97
41.14
39.98
42.14
44.44
45.85
47.7
51.13
57.81
63.92
72.17
81.45
88.52
- -
Tangible Book Value per Share
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
Basic Weighted Avg Shares
829
551
561
567
574
536
625
619
764
849
964
1,105
924
1,079
1,116
1,050
1,106
Sales/Revenue/Turnover
0.76
2.84
-2.83
-5.97
-3.19
15.52
9.05
3.44
-0.6
5.33
10.08
8.63
7.95
7.22
3.09
1.68
-3.03
Operating Margin (%)
11
10
47
91
61
8
28
31
31
32
12
17
13
20
22
21
23
Depreciation Expense
9
5
-44
-52
-14
68
25
28
10
19
72
141
126
168
195
150
44
Net Income, GAAP
16.45
36.76
- -
- -
- -
29.69
55.32
39.51
63.29
36.25
32.81
27.96
20.81
18.88
24.01
10.11
25.91
Effective Tax Rate (%)
1.09
0.96
-7.78
-9.09
-2.44
12.77
4.03
4.53
1.32
2.18
7.52
12.75
13.62
15.55
17.47
14.3
3.96
Profit Margin (%)
256
324
212
205
714
754
749
744
718
747
884
1,066
1,167
1,329
1,458
1,584
- -
Working Capital
- -
27
62
42
- -
- -
5
6
4
2
- -
21
8
- -
- -
- -
- -
LT Debt
973
978
935
883
866
922
947
975
985
1,004
1,076
1,217
1,346
1,519
1,714
1,863
- -
Total Equity
0.2
0.92
- -
- -
- -
3.65
0.95
0.74
-0.64
1.69
4.74
5.44
3.96
4.04
1.18
0.62
- -
Return on Invested Capital (%)
0.86
0.49
- -
- -
- -
6.69
2.93
3.14
1.17
1.91
6.96
12.04
9.57
11.59
11.88
8.34
- -
Return on Capital (%)
0.93
0.54
-4.57
-5.67
-1.6
7.66
2.7
2.92
1.03
1.86
6.97
12.29
9.82
11.71
12.06
8.39
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
25
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
1,635
978
1,421

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,109
- -
Cash, Cash Equivalents & STI
- -
1,379
- -
Accounts Receivable, Net
- -
408
- -
Inventories
- -
133
- -
Total Current Liabilities
- -
525
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
25
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.39%
11.61%
8.66%
Free Cash Flow
-172.93%
-46.59%
-12.9%
Net Income, GAAP
36.87%
22.06%
-23.04%
Sales/Revenue/Turnover
7.63%
2.5%
-5.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
214
249
262
399
1,116
2026
191
263
290
314
1,050
2027
239
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.42
3.66
4.23
-0.95
9.27
2026
5.59
0.05
0.9
0.66
7.13
2027
0.49
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Alpa Laboratories Limited manufactures and sells pharmaceutical finished dosage forms in India. The company produces a wide range of ethical, generic, and over-the-counter (OTC) drugs for human and veterinary use, including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams, and gels; its product portfolio covers therapeutic categories such as anti-infectives (antibacterials, antibiotics, antifungals, antiprotozoals, antivirals), analgesics, anti-inflammatory drugs, cough and cold preparations, cardiovascular drugs, anti-diabetics, nutritional supplements, psychotropic drugs, skin care preparations, and ear and eye care products. Alpa Laboratories operates WHO-GMP and ISO 9001:2000 certified manufacturing facilities at Pigdamber, near Indore, Madhya Pradesh, spanning 1.20 acres with dedicated production areas designed for high output and quality; it sells products under its own brands through distributors, retail chemists, pharmacy stores, and hospitals, while also serving as a contract manufacturer for Indian and multinational companies. Founded in 1967 and headquartered in Indore, India, the company exports to South and Central America, Africa, Asia, Russia, Ukraine, Kazakhstan, and other international markets. In recent developments, Alpa Laboratories announced the acquisition of land at Pithampur for expansion; appointed Ms. Srashti Chopra as Company Secretary and Compliance Officer; changed the designation of Mr. Vitthal Kothana from Non-Executive to Executive Director; and reported consolidated financial results for quarters ended December 2024, September 2024, June 2025, and the full year ended March 31, 2025, alongside multiple disclosures under SEBI (SAST) Regulations for share acquisitions by promoters and related parties.